Related Experiment Video
Updated: Jun 12, 2025

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
Published on: January 10, 2025
Impact of Gender-Affirming Hormonal Therapy on Cardiovascular Risk Factors in Transgender Health: An Updated
Saad Ur Rahman1, Nouraldeen Manasrah2, Nomesh Kumar3
1Division of Cardiovascular Medicine, Lahey Hospital and Medical Center, Burlington, Massachusetts, USA.
Gender-affirming hormone therapy (GAHT) impacts lipid profiles in transgender individuals, increasing LDL and triglycerides in transmasculine patients and triglycerides in transfeminine patients. Further research is needed to understand clinical outcomes.
Area of Science:
- Endocrinology
- Cardiovascular Science
- Transgender Health
Background:
- Gender-affirming hormone therapy (GAHT) is widely used by transgender individuals.
- The effects of GAHT on lipid profiles and cardiovascular health require further investigation.
Purpose of the Study:
- To systematically review and meta-analyze the impact of GAHT on lipid profiles.
- To assess changes in metabolic cardiovascular risk factors in transgender populations undergoing GAHT.
Main Methods:
- Systematic review and meta-analysis of observational studies and randomized controlled trials.
- Searched MEDLINE/PubMed, Embase, and Cochrane Central registry for studies on lipid profile changes in transfeminine (TF) and transmasculine (TM) individuals.
- Analyzed lipid profile changes pre- and post-GAHT using R-statistical software.
Main Results:
- Included 1,241 TM and 992 TF patients from 12 observational studies and 12 RCTs.
- Transmasculine patients showed increased LDL, triglycerides, and total cholesterol, with decreased HDL post-GAHT.
- Transfeminine patients exhibited increased triglyceride levels post-GAHT.
Conclusions:
- GAHT significantly alters lipid profiles in transgender individuals.
- Additional research is necessary to elucidate the clinical implications of these lipid profile changes.
More Related Videos
06:18An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
07:37Author Spotlight: Advancing Human Ovarian Repair and Cancer Studies with Surface Epithelium Organoids
Published on: August 16, 2024
Related Concept Videos
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Hormonal Regulation of Blood Pressure
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
Hormonal Regulation
Factors Influencing Heart Rate
Let us explore the significant factors affecting heart rate, including age, body temperature, posture, acute pain, chemical influences,...
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...